Pharmacokinetics and pharmacokinetic-dynamic relationship between rapacuronium (Org 9487) and its 3-desacetyl metabolite (Org 9488)

Anesthesia and Analgesia

Volumn 88, Issue 3, 1999, Pages 640-647

  Schiere, Sjouke ^a   Proost, Johannes H ^a   Schuringa, Marriët ^a   Wierda, Mark K H ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3 DESACETYLRAPACURONIUM; MUSCLE RELAXANT AGENT; RAPACURONIUM BROMIDE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DOSE TIME EFFECT RELATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MUSCLE RELAXATION; NEUROMUSCULAR BLOCKING; PRIORITY JOURNAL; RECEPTOR AFFINITY;

EID: 0032975279     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000539-199903000-00032     Document Type: Article

References (17)

1. Wierda JMKH, Van den Broek L, Proost JH, et al. Time course of action and endotracheal intubating conditions of Org 9487, a new short-acting steroidal muscle relaxant: a comparison with succinylcholine. Anesth Analg 1993;77:579-84.
2. Kahwaji R, Bevan DR, Bikhazi G, et al. Dose-ranging study in younger adult and elderly patients of Org 9487, a new, rapidonset, short duration muscle relaxant. Anesth Analg 1997;84: 1011-8.
3. Schiere S, Van den Broek L, Proost JH, et al. Comparison of vecuronium with Org 9487 and their interaction. Can J Anaesth 1997;44:1138-43.
4. Van den Broek L, Wierda JMKH, Smeulers NJ, Proost JH. Pharmacodynamics and pharmacokinetics of an infusion of Org 9487, a new short-acting steroidal neuromuscular blocking agent. Br J Anaesth 1994;73:331-5.
5. Donati F. Onset of action of relaxants. Can J Anaesth 1988;35: S52-8.
6. Proost JH, Wierda JMKH, Meijer DKF. Structure-pharmacokinetic and pharmacodynamic relationships of steroidal neuromuscular blocking agents. In: Fukushima K, Ochiai R, eds. Muscle relaxants: physiologic and pharmacologie aspects. Tokyo: Springer-Verlag, 1995:205-12.
7. Sheiner LB, Stanski DR, Vozeh S, et al. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979;25:358-71.
8. Rowaan CJ, Vandenbrom RHG, Wierda JMKH. The relaxometer: a complete and comprehensive computercontrolled neuromuscular transmission measurement system developed for clinical research on muscle relaxants. J Clin Monit 1993;9:38-44.
9. Bevan DR, Donati F. Muscle relaxants of the future. Semin Anesth 1992;! 1:123-30.
10. Wierda JMKH, Proost JH, Muir AW, Marshall RJ. Design of drugs for rapid onset. Anaesth Pharmacol Rev 1993;l:57-68.
11. Sohn YJ, Bencini AF, Scaf AHJ, et al. Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients. Anesth Analg 1986;65:233-9.
12. Wierda JMKH, Kleef UW, Lambalk LM, et al. The pharmacodynamics and pharmacokinetics of Org 9426, a new nondepolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl. Can J Anaesth 1991;38:430-5.
13. Proost JH, Roggeveld J, Wierda JMKH, Meijer DKF. Relationship between chemical structure and physicochemical properties of series of bulky organic cations and their hepatic uptake and biliary excretion rates. J Pharmacol Exp Ther 1997;282: 715-26.
14. Bencini AF, Scaf AH], Sohn YJ, et al. Hepatobiliary disposition of vecuronium bromide in man. Br J Anaesth 1986;58:988-95.
15. Khuenl-Brady KS, Castagnoli KP, Canfell PC, et al. The neuromuscular blocking effects and pharmacokinetics of Org 9426 and Org 9616 in the cat. Anesthesiology 1990;72:669-74.
16. Wierda JMKH, Proost JH, Schiere S, Hommes FDM. Pharmacokinetics and pharmacokinetic/dynamic relationship of rocuronium bromide in humans. Eur J Anaesthesiol 1994;11(Suppl 9):66-74.
17. Sparr HJ, VVierda JMKH, Proost JH, et al. Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. Br J Anaesth 1997;78:267-73.